Fiche centre
Hospital de Braga
Braga — Portugal
Essais liés10clinical trials
VilleBragalocalisation
PaysPortugallocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT04544436
Essais cliniques associés
10| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Ocrelizumab | SEP | Phase 3 | NCT05123703 | Operetta 2 — A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS) | ACTIVE_NOT_RECRUITING |
| Ocrelizumab | SEP | Phase 3 | NCT04544436 | MUSETTE — A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS) | ACTIVE_NOT_RECRUITING |
| Prasinezumab | Parkinson | Phase 3 | NCT07174310 | PARAISO — A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease | RECRUITING |
| Eptinezumab | Migraine | Phase 3 | NCT05897320 | PROSPECT-1 — A Study of Eptinezumab in Pediatric Participants With Episodic Migraine | RECRUITING |
| KarXT | Alzheimer | Phase 3 | NCT06976203 | A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2) | RECRUITING |
| Ocrelizumab | SEP | Phase 3 | NCT04035005 | O'HAND — A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis | ACTIVE_NOT_RECRUITING |
| RO7121932 IV | SEP | Phase 1 | NCT05704361 | A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis | ACTIVE_NOT_RECRUITING |
| Ocrelizumab | SEP | Phase 3 | NCT04548999 | GAVOTTE — A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS) | ACTIVE_NOT_RECRUITING |
| Ponesimod | SEP | Phase 3 | NCT03232073 | Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis | COMPLETED |
| Fenebrutinib | SEP | Phase 3 | NCT04586010 | FENhance — A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) | ACTIVE_NOT_RECRUITING |